User login
A gluten-free diet reduced stool frequency as well as small bowel permeability in irritable bowel syndrome patients without celiac disease.
The findings, published in the May issue of Gastroenterology, "support the need for further clinical intervention studies to evaluate the clinical effects of gluten withdrawal in patients with diarrhea-predominant IBS," reported Dr. Maria I. Vazquez-Roque and her colleagues.
Dr. Vasquez-Roque, of the Mayo Clinic’s Clinical Enteric Neuroscience Translational and Epidemiological Research Program, in Rochester, Minn., and her colleagues recruited 45 subjects (43 women) from a database of more than 800 patients with irritable bowel syndrome who had been evaluated at the Mayo Clinic.
All patients had diarrhea-predominant IBS (IBS-D), were not on a gluten-free diet prior to the study, and did not have celiac disease.
They were randomized to either a gluten-free diet or a gluten-containing diet for 28 days. Patients’ meals and snacks were ingested or prepared in the Mayo Clinical Research Unit, and study participants were asked to eat only the foods provided by the study dietitians during the entire study period, the authors wrote. Dietitians assessed diet compliance using direct questioning of participants.
After 28 days of the study, the investigators looked at several clinical and histologic markers.
First, they tallied stool frequency, and found that patients on the gluten-containing diet had more stools per day than gluten-free patients did (P = .04), with a 95% confidence interval for the absolute difference between number of stools per day at –0.652 to –0.015 (Gastroenterology 2013 Jan. 28 [doi: 10.1053/j.gastro.2013.01.049]).
"While the absolute difference in stool frequency is small, it is important to appreciate that this increased frequency is on a background of the typical increase in stool frequency (average 2.6 bowel movements/day at baseline) and consistency in patients with IBS-D," the authors wrote.
This effect was more pronounced in subjects who were HLA-DQ2 or 8 positive (95% CI, –1.005 to –0.092; P = .019), they added.
Next, the investigators looked at small bowel permeability.
They found increased small bowel permeability with gluten-containing diet patients relative to their gluten-free counterparts, based on both cumulative mannitol excretion levels and lactulose:mannitol ratio. Similarly, this effect was more pronounced in HLA-DQ2 or 8 positive patients.
"While the clinical significance of these changes in permeability is not demonstrated in the current study, the abundant experimental evidence from the published literature is that increased mucosal permeability enhances inflammation and leads to increased sensitivity," they wrote.
Finally, the authors looked at tight-junction mRNA expression.
"Alterations in intestinal permeability and jejunal mucosal tight junction (TJ) signaling have been described in IBS-D, including postinfectious IBS-D," they wrote.
They found that expressions of ZO-1, occludin, and claudin-1 mRNA in colonic mucosa were significantly lower with the gluten-containing diet, compared with the gluten-free patients, particularly in subjects with HLA-DQ2 or 8 positive status.
There were no significant variations in tight junction signaling in the small bowel mucosa.
The authors conceded several limitations to their study. For one, it "did not evaluate effects of gluten on the microbiome, afferent functions, or cytokine expression in the mucosal biopsies from patients before and after the interventions. These would be interesting parameters to include in future studies," they wrote.
Additionally, "our study does not specifically address the effects of gluten protein per se, and it is possible that other proteins in wheat flour may be responsible for the changes observed."
Nevertheless, "our data provide mechanistic explanations for the observation that gluten withdrawal may improve patient symptoms in IBS," they concluded.
The researchers disclosed receiving funding for this study from the National Institutes of Health. One investigator also disclosed having received grants from Alba Therapeutics, maker of the drug larazotide, used in celiac disease.
Recently, we have seen the emergence of
nonceliac gluten sensitivity as a distinct clinical entity. It is as if the medical
community has caught up to the food industry and the patients because there has
been an explosion in the availability of gluten-free foods and some patients,
without celiac disease, have been telling us they feel better when gluten has
been withdrawn from their diet.
A recent study from Australia demonstrated in a double-blind,
randomized study of a gluten-containing diet versus a gluten-free diet
that individuals with irritable bowel syndrome (IBS) who had self-selected as
being gluten sensitive experienced more gastrointestinal symptoms and fatigue
when exposed to the gluten-containing diet.
The investigators from the Mayo Clinic in Rochester,
Minn. extended these studies to patients with diarrhea-predominant
IBS who had not self-selected as being gluten sensitive. They demonstrated that
the gluten-free diet reduced stool frequency and small bowel permeability and
that the effect was most prominent in those who possessed the celiac disease at
risk genes, HLA DQ2 and DQ8.
Gluten is not fully digested by our digestive system,
unlike meat protein. The large amino acid molecules that remain after digestion
appear responsible for the development of celiac disease in some individuals
who are HLA DQ2 or -8 positive. It now appears that gluten (or other
proteins found in wheat) may induce changes that result in symptoms in patients
labeled as having IBS.
So those that have already self-diagnosed as being
gluten sensitive may in fact just be the tip of the iceberg of gluten
sensitivity.
Peter H.R. Green, M.D., is the Director of
the Celiac Disease Center, Columbia University, New York, and professor of
clinical medicine at the College of Physicians and Surgeons. Dr. Green is on
the scientific advisory boards for Alvine Pharmaceuticals and ImmusanT.
Recently, we have seen the emergence of
nonceliac gluten sensitivity as a distinct clinical entity. It is as if the medical
community has caught up to the food industry and the patients because there has
been an explosion in the availability of gluten-free foods and some patients,
without celiac disease, have been telling us they feel better when gluten has
been withdrawn from their diet.
A recent study from Australia demonstrated in a double-blind,
randomized study of a gluten-containing diet versus a gluten-free diet
that individuals with irritable bowel syndrome (IBS) who had self-selected as
being gluten sensitive experienced more gastrointestinal symptoms and fatigue
when exposed to the gluten-containing diet.
The investigators from the Mayo Clinic in Rochester,
Minn. extended these studies to patients with diarrhea-predominant
IBS who had not self-selected as being gluten sensitive. They demonstrated that
the gluten-free diet reduced stool frequency and small bowel permeability and
that the effect was most prominent in those who possessed the celiac disease at
risk genes, HLA DQ2 and DQ8.
Gluten is not fully digested by our digestive system,
unlike meat protein. The large amino acid molecules that remain after digestion
appear responsible for the development of celiac disease in some individuals
who are HLA DQ2 or -8 positive. It now appears that gluten (or other
proteins found in wheat) may induce changes that result in symptoms in patients
labeled as having IBS.
So those that have already self-diagnosed as being
gluten sensitive may in fact just be the tip of the iceberg of gluten
sensitivity.
Peter H.R. Green, M.D., is the Director of
the Celiac Disease Center, Columbia University, New York, and professor of
clinical medicine at the College of Physicians and Surgeons. Dr. Green is on
the scientific advisory boards for Alvine Pharmaceuticals and ImmusanT.
Recently, we have seen the emergence of
nonceliac gluten sensitivity as a distinct clinical entity. It is as if the medical
community has caught up to the food industry and the patients because there has
been an explosion in the availability of gluten-free foods and some patients,
without celiac disease, have been telling us they feel better when gluten has
been withdrawn from their diet.
A recent study from Australia demonstrated in a double-blind,
randomized study of a gluten-containing diet versus a gluten-free diet
that individuals with irritable bowel syndrome (IBS) who had self-selected as
being gluten sensitive experienced more gastrointestinal symptoms and fatigue
when exposed to the gluten-containing diet.
The investigators from the Mayo Clinic in Rochester,
Minn. extended these studies to patients with diarrhea-predominant
IBS who had not self-selected as being gluten sensitive. They demonstrated that
the gluten-free diet reduced stool frequency and small bowel permeability and
that the effect was most prominent in those who possessed the celiac disease at
risk genes, HLA DQ2 and DQ8.
Gluten is not fully digested by our digestive system,
unlike meat protein. The large amino acid molecules that remain after digestion
appear responsible for the development of celiac disease in some individuals
who are HLA DQ2 or -8 positive. It now appears that gluten (or other
proteins found in wheat) may induce changes that result in symptoms in patients
labeled as having IBS.
So those that have already self-diagnosed as being
gluten sensitive may in fact just be the tip of the iceberg of gluten
sensitivity.
Peter H.R. Green, M.D., is the Director of
the Celiac Disease Center, Columbia University, New York, and professor of
clinical medicine at the College of Physicians and Surgeons. Dr. Green is on
the scientific advisory boards for Alvine Pharmaceuticals and ImmusanT.
A gluten-free diet reduced stool frequency as well as small bowel permeability in irritable bowel syndrome patients without celiac disease.
The findings, published in the May issue of Gastroenterology, "support the need for further clinical intervention studies to evaluate the clinical effects of gluten withdrawal in patients with diarrhea-predominant IBS," reported Dr. Maria I. Vazquez-Roque and her colleagues.
Dr. Vasquez-Roque, of the Mayo Clinic’s Clinical Enteric Neuroscience Translational and Epidemiological Research Program, in Rochester, Minn., and her colleagues recruited 45 subjects (43 women) from a database of more than 800 patients with irritable bowel syndrome who had been evaluated at the Mayo Clinic.
All patients had diarrhea-predominant IBS (IBS-D), were not on a gluten-free diet prior to the study, and did not have celiac disease.
They were randomized to either a gluten-free diet or a gluten-containing diet for 28 days. Patients’ meals and snacks were ingested or prepared in the Mayo Clinical Research Unit, and study participants were asked to eat only the foods provided by the study dietitians during the entire study period, the authors wrote. Dietitians assessed diet compliance using direct questioning of participants.
After 28 days of the study, the investigators looked at several clinical and histologic markers.
First, they tallied stool frequency, and found that patients on the gluten-containing diet had more stools per day than gluten-free patients did (P = .04), with a 95% confidence interval for the absolute difference between number of stools per day at –0.652 to –0.015 (Gastroenterology 2013 Jan. 28 [doi: 10.1053/j.gastro.2013.01.049]).
"While the absolute difference in stool frequency is small, it is important to appreciate that this increased frequency is on a background of the typical increase in stool frequency (average 2.6 bowel movements/day at baseline) and consistency in patients with IBS-D," the authors wrote.
This effect was more pronounced in subjects who were HLA-DQ2 or 8 positive (95% CI, –1.005 to –0.092; P = .019), they added.
Next, the investigators looked at small bowel permeability.
They found increased small bowel permeability with gluten-containing diet patients relative to their gluten-free counterparts, based on both cumulative mannitol excretion levels and lactulose:mannitol ratio. Similarly, this effect was more pronounced in HLA-DQ2 or 8 positive patients.
"While the clinical significance of these changes in permeability is not demonstrated in the current study, the abundant experimental evidence from the published literature is that increased mucosal permeability enhances inflammation and leads to increased sensitivity," they wrote.
Finally, the authors looked at tight-junction mRNA expression.
"Alterations in intestinal permeability and jejunal mucosal tight junction (TJ) signaling have been described in IBS-D, including postinfectious IBS-D," they wrote.
They found that expressions of ZO-1, occludin, and claudin-1 mRNA in colonic mucosa were significantly lower with the gluten-containing diet, compared with the gluten-free patients, particularly in subjects with HLA-DQ2 or 8 positive status.
There were no significant variations in tight junction signaling in the small bowel mucosa.
The authors conceded several limitations to their study. For one, it "did not evaluate effects of gluten on the microbiome, afferent functions, or cytokine expression in the mucosal biopsies from patients before and after the interventions. These would be interesting parameters to include in future studies," they wrote.
Additionally, "our study does not specifically address the effects of gluten protein per se, and it is possible that other proteins in wheat flour may be responsible for the changes observed."
Nevertheless, "our data provide mechanistic explanations for the observation that gluten withdrawal may improve patient symptoms in IBS," they concluded.
The researchers disclosed receiving funding for this study from the National Institutes of Health. One investigator also disclosed having received grants from Alba Therapeutics, maker of the drug larazotide, used in celiac disease.
A gluten-free diet reduced stool frequency as well as small bowel permeability in irritable bowel syndrome patients without celiac disease.
The findings, published in the May issue of Gastroenterology, "support the need for further clinical intervention studies to evaluate the clinical effects of gluten withdrawal in patients with diarrhea-predominant IBS," reported Dr. Maria I. Vazquez-Roque and her colleagues.
Dr. Vasquez-Roque, of the Mayo Clinic’s Clinical Enteric Neuroscience Translational and Epidemiological Research Program, in Rochester, Minn., and her colleagues recruited 45 subjects (43 women) from a database of more than 800 patients with irritable bowel syndrome who had been evaluated at the Mayo Clinic.
All patients had diarrhea-predominant IBS (IBS-D), were not on a gluten-free diet prior to the study, and did not have celiac disease.
They were randomized to either a gluten-free diet or a gluten-containing diet for 28 days. Patients’ meals and snacks were ingested or prepared in the Mayo Clinical Research Unit, and study participants were asked to eat only the foods provided by the study dietitians during the entire study period, the authors wrote. Dietitians assessed diet compliance using direct questioning of participants.
After 28 days of the study, the investigators looked at several clinical and histologic markers.
First, they tallied stool frequency, and found that patients on the gluten-containing diet had more stools per day than gluten-free patients did (P = .04), with a 95% confidence interval for the absolute difference between number of stools per day at –0.652 to –0.015 (Gastroenterology 2013 Jan. 28 [doi: 10.1053/j.gastro.2013.01.049]).
"While the absolute difference in stool frequency is small, it is important to appreciate that this increased frequency is on a background of the typical increase in stool frequency (average 2.6 bowel movements/day at baseline) and consistency in patients with IBS-D," the authors wrote.
This effect was more pronounced in subjects who were HLA-DQ2 or 8 positive (95% CI, –1.005 to –0.092; P = .019), they added.
Next, the investigators looked at small bowel permeability.
They found increased small bowel permeability with gluten-containing diet patients relative to their gluten-free counterparts, based on both cumulative mannitol excretion levels and lactulose:mannitol ratio. Similarly, this effect was more pronounced in HLA-DQ2 or 8 positive patients.
"While the clinical significance of these changes in permeability is not demonstrated in the current study, the abundant experimental evidence from the published literature is that increased mucosal permeability enhances inflammation and leads to increased sensitivity," they wrote.
Finally, the authors looked at tight-junction mRNA expression.
"Alterations in intestinal permeability and jejunal mucosal tight junction (TJ) signaling have been described in IBS-D, including postinfectious IBS-D," they wrote.
They found that expressions of ZO-1, occludin, and claudin-1 mRNA in colonic mucosa were significantly lower with the gluten-containing diet, compared with the gluten-free patients, particularly in subjects with HLA-DQ2 or 8 positive status.
There were no significant variations in tight junction signaling in the small bowel mucosa.
The authors conceded several limitations to their study. For one, it "did not evaluate effects of gluten on the microbiome, afferent functions, or cytokine expression in the mucosal biopsies from patients before and after the interventions. These would be interesting parameters to include in future studies," they wrote.
Additionally, "our study does not specifically address the effects of gluten protein per se, and it is possible that other proteins in wheat flour may be responsible for the changes observed."
Nevertheless, "our data provide mechanistic explanations for the observation that gluten withdrawal may improve patient symptoms in IBS," they concluded.
The researchers disclosed receiving funding for this study from the National Institutes of Health. One investigator also disclosed having received grants from Alba Therapeutics, maker of the drug larazotide, used in celiac disease.
FROM GASTROENTEROLOGY
Major finding: Irritable bowel syndrome patients on a gluten-free diet had fewer bowel movements per day than did gluten-consuming counterparts (P = .04).
Data source: A 4-week trial of 45 patients with diarrhea-predominant irritable bowel syndrome, randomized to a gluten-free or gluten-containing diet.
Disclosures: The researchers disclosed receiving funding for this study from the National Institutes of Health. One investigator also disclosed having received grants from Alba Therapeutics, maker of the drug larazotide, used in celiac disease.